[go: up one dir, main page]

WO2008034122A3 - Hindered ester-based biodegradable linkers for oligonucleotide delivery - Google Patents

Hindered ester-based biodegradable linkers for oligonucleotide delivery Download PDF

Info

Publication number
WO2008034122A3
WO2008034122A3 PCT/US2007/078597 US2007078597W WO2008034122A3 WO 2008034122 A3 WO2008034122 A3 WO 2008034122A3 US 2007078597 W US2007078597 W US 2007078597W WO 2008034122 A3 WO2008034122 A3 WO 2008034122A3
Authority
WO
WIPO (PCT)
Prior art keywords
based biodegradable
hindered ester
oligonucleotide delivery
biodegradable linkers
linkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/078597
Other languages
French (fr)
Other versions
WO2008034122A2 (en
Inventor
Hong Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Priority to AU2007296054A priority Critical patent/AU2007296054B2/en
Priority to CA002662978A priority patent/CA2662978A1/en
Priority to MX2009002859A priority patent/MX2009002859A/en
Priority to JP2009528517A priority patent/JP2010503707A/en
Priority to EP07842576A priority patent/EP2063709A2/en
Publication of WO2008034122A2 publication Critical patent/WO2008034122A2/en
Publication of WO2008034122A3 publication Critical patent/WO2008034122A3/en
Priority to IL197516A priority patent/IL197516A0/en
Priority to US12/402,743 priority patent/US8110559B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides hindered ester-based biodegradable linkers for the delivery of oligonucleotides in vivo, as well as method of making and using the same.
PCT/US2007/078597 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery Ceased WO2008034122A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2007296054A AU2007296054B2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
CA002662978A CA2662978A1 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
MX2009002859A MX2009002859A (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery.
JP2009528517A JP2010503707A (en) 2006-09-15 2007-09-15 Hindered ester biodegradable linkers for oligonucleotide delivery
EP07842576A EP2063709A2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery
IL197516A IL197516A0 (en) 2006-09-15 2009-03-10 Ester-based polymeric delivery systems
US12/402,743 US8110559B2 (en) 2006-09-15 2009-03-12 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84502806P 2006-09-15 2006-09-15
US60/845,028 2006-09-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/402,743 Continuation US8110559B2 (en) 2006-09-15 2009-03-12 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Publications (2)

Publication Number Publication Date
WO2008034122A2 WO2008034122A2 (en) 2008-03-20
WO2008034122A3 true WO2008034122A3 (en) 2008-10-30

Family

ID=39184642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078597 Ceased WO2008034122A2 (en) 2006-09-15 2007-09-15 Hindered ester-based biodegradable linkers for oligonucleotide delivery

Country Status (9)

Country Link
EP (1) EP2063709A2 (en)
JP (1) JP2010503707A (en)
KR (1) KR20090055623A (en)
CN (1) CN101534643A (en)
AU (1) AU2007296054B2 (en)
CA (1) CA2662978A1 (en)
IL (1) IL197516A0 (en)
MX (1) MX2009002859A (en)
WO (1) WO2008034122A2 (en)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201100812A1 (en) 2006-04-03 2012-06-29 Сантарис Фарма А/С PHARMACEUTICAL COMPOSITION
JP5198430B2 (en) 2006-04-03 2013-05-15 サンタリス ファーマ アー／エス Pharmaceutical composition comprising antimiRNA antisense oligonucleotide
KR20090083334A (en) * 2006-09-15 2009-08-03 엔존 파마슈티컬즈, 인코포레이티드 Polyalkylene oxides with hindered ester based biodegradable linkers
CA2664271A1 (en) * 2006-11-27 2008-06-12 Enzon Pharmaceuticals, Inc. Polymeric short interfering rna conjugates
DK2149605T3 (en) 2007-03-22 2013-09-30 Santaris Pharma As Short RNA antagonist compounds to modulate the desired mRNA
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
TW200848077A (en) 2007-05-01 2008-12-16 Santaris Pharma As Compounds for the modulation of beta-cantenin expression
AU2008250033A1 (en) 2007-05-11 2008-11-20 Enzon Pharmaceuticals, Inc. RNA antagonist compounds for the modulation of HER3
EP2205734A2 (en) 2007-09-24 2010-07-14 Noxxon Pharma AG C5a BINDING NUCLEIC ACIDS
DK2623599T3 (en) 2007-10-04 2019-04-08 Roche Innovation Ct Copenhagen As Micromirers
WO2009068033A2 (en) 2007-11-26 2009-06-04 Santaris Pharma A/S Lna antagonists targeting the androgen receptor
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
TW200927176A (en) 2007-12-03 2009-07-01 Santaris Pharma As RNA antagonist compounds for the modulation of PIK3CA expression
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
AU2009282747B2 (en) * 2008-08-22 2015-04-02 Takeda Pharmaceutical Company Limited Polymeric benzyl carbonate-derivatives
WO2010108657A2 (en) 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
EP2421970B1 (en) 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
JP2012529279A (en) 2009-06-12 2012-11-22 サンタリス ファーマ アー／エス Novel powerful anti-APOB antisense compounds
EP2456870A1 (en) 2009-07-21 2012-05-30 Santaris Pharma A/S Antisense oligomers targeting pcsk9
ES2833035T3 (en) 2009-07-31 2021-06-14 Ascendis Pharma As Biodegradable water insoluble hydrogels based on polyethylene glycol
WO2011012719A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Long acting insulin composition
CA2769340C (en) 2009-07-31 2018-09-11 Harald Rau Prodrugs comprising an insulin linker conjugate
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
WO2011131371A1 (en) 2010-04-21 2011-10-27 Noxxon Pharma Ag Lipid binding nucleic acids
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
WO2012025251A1 (en) 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
SG10201506725QA (en) 2010-09-09 2015-10-29 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment
WO2012034942A1 (en) 2010-09-13 2012-03-22 Santaris Pharma A/S Compounds for the modulation of aurora kinase b expression
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
JP2014503187A (en) 2010-10-29 2014-02-13 ノクソン ファーマ エージー Use of hepcidin-binding nucleic acids to remove hepcidin from the body
EP2646553A4 (en) 2010-11-12 2015-01-07 Santaris Pharma As Compositions and methods for treating androgen receptor dependent disorders including cancers
WO2012066092A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of aurora kinase a expression
WO2012066093A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
KR20140026357A (en) 2011-01-10 2014-03-05 녹손 파르마 아게 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2012110457A2 (en) 2011-02-14 2012-08-23 Santaris Pharma A/S Compounds for the modulation of osteopontin expression
WO2012143427A1 (en) 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
US20140127159A1 (en) 2011-06-23 2014-05-08 Stella Aps HCV Combination Therapy
EP2726611A1 (en) 2011-06-30 2014-05-07 Stella ApS Hcv combination therapy
WO2013000855A1 (en) 2011-06-30 2013-01-03 Santaris Pharma A/S Hcv combination therapy
PT2581448E (en) * 2011-10-13 2015-05-21 Institut National De La Santé Et De La Rech Médicale (Inserm) DNA TRICYCLO-PHOSPHOROTIOATE
AU2012325233A1 (en) 2011-10-21 2014-04-24 Noxxon Pharma Ag Glucagon binding nucleic acids
CA2853328A1 (en) 2011-11-07 2013-05-16 Stella Aps Prognostic method for checking efficacy of micro rna-122 inhibitors in hcv+ patients
AU2012334045A1 (en) 2011-11-11 2014-04-24 Santaris Pharma A/S Compounds for the modulation of SMN2 splicing
CN104136612A (en) 2012-01-10 2014-11-05 诺松制药股份公司 Nucleic acid that specifically binds CGRP
ES2786007T3 (en) 2012-01-10 2020-10-08 Aptarion Biotech Ag New C5a-binding nucleic acids
EP2850192B1 (en) 2012-05-16 2023-11-01 APTARION biotech AG Enzymatic synthesis of l-nucleic acids
HK1214297A1 (en) 2012-11-15 2016-07-22 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
WO2014080004A1 (en) 2012-11-26 2014-05-30 Santaris Pharma A/S Compositions and methods for modulation of fgfr3 expression
WO2014207232A1 (en) 2013-06-27 2014-12-31 Santaris Pharma A/S Antisense oligomers and conjugates targeting pcsk9
JP2017502075A (en) 2013-11-04 2017-01-19 ノクソン ファーマ エージー Means and methods for the treatment of kidney disorders
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
GB201414098D0 (en) 2014-08-08 2014-09-24 Illumina Cambridge Ltd Modified nucleotide linkers
DK3234131T3 (en) 2014-12-16 2020-06-29 Roche Innovation Ct Copenhagen As Method of screening for chiral toxicity
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
MX2018008061A (en) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Cnp prodrugs with large carrier moieties.
CA3007979C (en) 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
IL259658B2 (en) 2016-01-08 2024-06-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with reduced side effects
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
MA45809B1 (en) 2016-03-01 2024-12-31 Ascendis Pharma Bone Diseases A/S PTH PRODRUGS
EP3443095A1 (en) 2016-04-15 2019-02-20 Noxxon Pharma AG Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
SG11201809468XA (en) * 2016-04-29 2018-11-29 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
KR20240013849A (en) 2016-09-29 2024-01-30 아센디스 파마 본 디지즈 에이/에스 Dosage regimen for a controlled-release pth compound
HUE070273T2 (en) 2016-09-29 2025-05-28 Ascendis Pharma Bone Diseases As Controlled-release pth compounds
HRP20230383T1 (en) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
IL290054B2 (en) 2016-09-29 2024-03-01 Ascendis Pharma Growth Disorders As Combined treatment with CNP agonists with controlled release
JP7216006B2 (en) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド Hydrogel Crosslinked Hyaluronic Acid Prodrug Compositions and Methods
KR102141124B1 (en) * 2018-01-30 2020-08-04 (주)바이오니아 Double-stranded Oligonucleotide Complex comprising Double― stranded miRNA and Uses thereof
US20210008168A1 (en) 2018-03-28 2021-01-14 Ascendis Pharma A/S Conjugates
EP3773680A1 (en) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Il-2 conjugates
EP3793685A1 (en) 2018-05-18 2021-03-24 F. Hoffmann-La Roche AG Pharmaceutical compositions for treatment of microrna related diseases
MA69295B1 (en) 2018-05-18 2025-10-31 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
CA3114272A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
CA3114329A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
CA3114056A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
AU2020204785A1 (en) 2019-01-04 2021-06-03 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
PH12021551591A1 (en) 2019-01-04 2022-04-18 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
WO2020141225A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Minimization of systemic inflammation
US12403182B2 (en) 2019-02-11 2025-09-02 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
BR112021014495A2 (en) 2019-02-11 2021-11-23 Ascendis Pharma Growth Disorders As Dry pharmaceutical formulations of cnp conjugates
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
US20230102309A1 (en) 2019-06-21 2023-03-30 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2021144249A1 (en) 2020-01-13 2021-07-22 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
US20230241217A1 (en) 2020-05-04 2023-08-03 Ascendis Pharma A/S Hydrogel irradiation
AU2021286177A1 (en) 2020-06-03 2022-12-01 Ascendis Pharma Oncology Division A/S IL-2 sequences and uses thereof
EP4204439A1 (en) 2020-08-28 2023-07-05 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
CN112047840A (en) * 2020-08-31 2020-12-08 山东药品食品职业学院 Synthesis method of 7-bromo-2, 2-dimethylheptanoic acid ethyl ester and product obtained by synthesis
JP2023543265A (en) 2020-09-28 2023-10-13 アセンディス ファーマ ボーン ディジージズ エー／エス Improving physical and mental well-being in patients with hypoparathyroidism
CA3212417A1 (en) 2021-04-01 2022-10-06 Kennett Sprogoe Use of long-acting growth hormone for treating inflammation-induced diseases
JPWO2022230990A1 (en) * 2021-04-28 2022-11-03
US20240382567A1 (en) 2021-09-22 2024-11-21 Ascendis Pharma Bone Diseases A/S Long-acting PTH compound treatments
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
JP2024546134A (en) 2021-12-13 2024-12-17 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Cancer treatment using TLR7/8 agonists
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of CNP compounds
KR20250025627A (en) 2022-06-21 2025-02-24 티엠이 파마 아게 Method of treating a tumor in a subject
EP4306640A1 (en) 2022-06-21 2024-01-17 TME Pharma AG Method for treating a tumor in a subject
JP2025537527A (en) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス PTH Treatment Regimen Comprising Two PTH Compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202434299A (en) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 Methods of producing hydrogel microspheres
TW202430223A (en) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 Drug conjugates for the treatment of ocular disorders
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
AU2024232125A1 (en) 2023-03-06 2025-08-28 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety
KR20250131829A (en) 2023-03-06 2025-09-03 아센디스 파마 에이에스 Drug compound comprising an albumin binding moiety
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
WO2024231442A1 (en) 2023-05-09 2024-11-14 Ascendis Pharma Oncology Division A/S Novel cancer treatments with il-2 conjugates
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
WO2025196240A1 (en) 2024-03-20 2025-09-25 Aptarion Biotech Ag Method of treating a disorder with a c5a inhibitor
EP4620474A1 (en) 2024-03-20 2025-09-24 APTARION biotech AG Method of treating a disorder with a c5a inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707813A (en) * 1990-05-15 1998-01-13 Diatron Corporation Nucleic acid probes and methods
WO2001013958A2 (en) * 1999-08-26 2001-03-01 Sydney Brenner Drug conjugates and methods of designing the same
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6887906B1 (en) * 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
CA2312975C (en) * 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
ATE268609T1 (en) * 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp POLYETHYLENE GLYCOL DERIVATIVES WITH ADJACENT REACTIVE GROUPS
JP3485023B2 (en) * 1999-05-20 2004-01-13 東亞合成株式会社 Nucleoside compound
KR100406739B1 (en) * 2000-04-15 2003-11-20 주식회사 코오롱 Aqueous-prodrug compound comprising moiety of paclitaxelor derivatives thereof, method of preparing same and pharmaceutical composition comprising same
JP2004518776A (en) * 2000-12-01 2004-06-24 エンゾン，インコーポレーテッド Tetrapartate prodrug
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
RU2394041C2 (en) * 2003-04-13 2010-07-10 Энзон Фармасьютикалз, Инк. Oligonucleotide polymeric prodrugs
KR20090083334A (en) * 2006-09-15 2009-08-03 엔존 파마슈티컬즈, 인코포레이티드 Polyalkylene oxides with hindered ester based biodegradable linkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707813A (en) * 1990-05-15 1998-01-13 Diatron Corporation Nucleic acid probes and methods
US6887906B1 (en) * 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6303569B1 (en) * 1997-12-30 2001-10-16 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
WO2001013958A2 (en) * 1999-08-26 2001-03-01 Sydney Brenner Drug conjugates and methods of designing the same

Also Published As

Publication number Publication date
EP2063709A2 (en) 2009-06-03
MX2009002859A (en) 2009-03-30
IL197516A0 (en) 2009-12-24
CA2662978A1 (en) 2008-03-20
JP2010503707A (en) 2010-02-04
CN101534643A (en) 2009-09-16
WO2008034122A2 (en) 2008-03-20
AU2007296054A1 (en) 2008-03-20
KR20090055623A (en) 2009-06-02
AU2007296054B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
WO2008034122A3 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
EP2097464A4 (en) Polyamide polyols and polyurethanes, methods for making and using, and products made therefrom
WO2006020768A3 (en) Chemically modified oligonucleotides
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
IL191147A0 (en) Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2007121131A3 (en) Medical devices including shape memory materials
WO2007136969A3 (en) Bioabsorbable magnesium-reinforced polymer stents
EP1942831A4 (en) Twist-down implant delivery technologies
GB0402131D0 (en) Delivery method
WO2008034007A3 (en) Medical devices
IL206395A (en) N-heterocyclyl-7-oxo-6-sulfooxy-1,6-diazabicyclo[3.2.1]octane-2-carboxamides and pharmaceutical compositions comprising them
WO2007121318A3 (en) Formulations for delivering insulin
IL179973A0 (en) Immunostimulatory oligonucleotide multimers
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2007103666A3 (en) Implantable medical endoprosthesis delivery systems
EP2063816A4 (en) Implants comprising biodegradable metals and method for manufacturing the same
IL194007A0 (en) Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2076557A4 (en) Polylysine dendrimer contrast agent
WO2007143086A3 (en) Delivery method
WO2008033300A8 (en) Bis (thiohydrazide amides) formulation
PT2977061T (en) Peroxide removal from drug delivery vehicle
PL2034015T3 (en) Immunostimulatory oligonucleotide and pharmaceutical application thereof
EP2001427A4 (en) Intra-ocular implant
EP2002808A4 (en) Stent delivery catheter
PL2094849T3 (en) Long term disease modification using immunostimulatory oligonucleotides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041936.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842576

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 435/MUMNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2662978

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002859

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009528517

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007296054

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007842576

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097007157

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007296054

Country of ref document: AU

Date of ref document: 20070915

Kind code of ref document: A